Trial · NCT01764737
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
NCT01764737, Phase 1, Completed, Vaccinex Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS. Trials, record NCT01764737. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01764737
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
- NCT number
- NCT01764737
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 50 participants, actual
- Lead sponsor
- Vaccinex Inc.
- Conditions
- Multiple Sclerosis
- Interventions
- VX15/2503, Placebo
- First posted
- 2013-01-10
- Last updated
- 2015-02-06
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety/Tolerability as determined by number of patients with adverse events | Up to 12 weeks depending on dose cohort | |
| Secondary | Half-life of VX15/2503 | Up to 12 weeks depending on dose cohort | |
| Secondary | Peak plasma concentration (Cmax) of VX15/2503 | Up to 12 weeks depending on dose cohort | |
| Secondary | Area under the plasma concentration versus time curve (AUC) of VX15/2503 | Up to 12 weeks depending on dose cohort | |
| Secondary | Number of patients who develop anti-drug antibody | Up to 12 weeks depending on dose cohort | |
| Other | Cellular Semaphorin 4D (SEMA4D; CD100) percent saturation | Up to 12 weeks depending on dose cohort | |
| Other | VX15/2503 dose level vs serum SEMA4D levels | Up to 12 weeks depending on dose cohort | |
| Other | Change in magnetic resonance imaging (MRI) parameters as compared to VX15/2503 dose level | Screening to 4 weeks post-dose | MRI parameters: * Number of T1 gadolinium (Gd)-enhancing lesions * Number of T2 lesions * Total volume of T1 and T2 lesions if the investigational site has the imaging processing capability |
| Other | VX15/2503 dose vs the change in Kurtzke Expanded Disability Status Scale | Up to 12 weeks depending on dose cohort |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01764737
GET https://conductscience.org/api/trials/v1/NCT01764737/registered